In episode 2 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss overcoming barriers to the use of oral JAK inhibitors. This activity focuses on the mechanistic rationale for the benefit and risk profiles of oral JAK inhibitors, how to address the black box warnings, and making treatment decisions based on patients’ values and goals.